Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells.
Experimental evolution has been used for various biotechnological applications including protein and microbial cell engineering, but less commonly in the field of oncolytic virotherapy. Here, we sought to adapt a rapidly evolving RNA virus to cells deficient for the tumor suppressor gene p53, a hall...
Guardado en:
Autores principales: | Raquel Garijo, Pablo Hernández-Alonso, Carmen Rivas, Jean-Simon Diallo, Rafael Sanjuán |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c084da314e344d8193753f27dfe89078 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Marie-Claude Bourgeois-Daigneault, et al.
Publicado: (2021) -
Correction: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Publicado: (2021) -
Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis
por: Amanda W. K. AuYeung, et al.
Publicado: (2021) -
The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress
por: Jinqiong Jiang, et al.
Publicado: (2021) -
Structure of the vesicular stomatitis virus N⁰-P complex.
por: Cédric Leyrat, et al.
Publicado: (2011)